PharmaShots | Incisive News in 3 Shots

Subscribe Now

enforce study

Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache

Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache

April 24, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us